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Background
Iron chelators for the treatment of malaria have proven
therapeutic activity in vitro and in vivo in both humans
and mice, but their clinical use has been limited by the
unsuitable adsorption and pharmacokinetic properties of
the few available chelators. FBS0701 is an oral iron chela-
tor currently in Phase 2 human studies for the treatment
of transfusional iron overload. The drug has very favorable
absorption and PK properties allowing for once-daily use
to deplete circulating free iron. Once-daily administration
of FBS0701 in humans at well tolerated doses can achieve
plasma concentrations in the high μMr a n g e .
Materials and methods
P. falciparum drug inhibition was performed with
Sybrgreen drug inhibition assays. Murine malaria was
initiated by intraperitoneal inoculum of Balb/c mice fol-
lowed for 30 days.
Results
FBS0701 has potent IC50 of 5 μM in contrast to the IC50
for deferiprone and deferoxamine at 15 and 30 μM
respectively. The FBS0701 iron chelator was not antago-
nistic to the quinoloines or artemisinin in P. falciparum
in vitro tests. In the P. berghei Thompson suppression
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Figure 1 Four mice were inoculated with 10 million lethal P.yoelii parasites. The survival curve shows complete protection with Day +1 dosing
and significant protection in animals pre-treated Day -7 and Day -1.
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prolonged survival, but did not cure mice. The number
of daily doses - one, three or seven - did not signifi-
cantly alter outcome in P. berghei infection. We then
pre-treated mice with a single oral dose of 100 mg/kg of
FBS0701 seven days or one day before infection with
lethal P. yoelii 17XL. We also treated with a single dose
one day after yoelii infection. All mice treated with a
single dose one day following infection survived to 30
days in Figure 1. All untreated mice died by day 11. All
FBS0701-treated mice had reduced parasitemia on day
three. On day 16, the surviving FBS0701-treated mice
had a significant reticulocytosis with more than 70%
reticulocytes. Only 10 to 20% of mature erythrocytes
were infected on day 16 in contrast to 40-60% of reticu-
locytes. By Day 23 post-infection, reticulocytosis and
parasitemia had resolved.
Conclusion
F B S 0 7 0 1d e m o n s t r a t e sas i n g l eo r a ld o s ec u r eo ft h e
lethal P. yoelii model. Significantly, this effect persists
after the chelator has cleared from plasma. FBS0701
may find clinically utility as monotherapy, a malarial
prophylactic or, more likely, in combination with other
antimalarials.
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